BOLT BIOTHERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.1 USD | -1.79% |
|
-5.17% | -1.79% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 182.7 | 48.96 | 42.52 | 41.94 | - | - |
| Enterprise Value (EV) 1 | -3.524 | -97.32 | 42.52 | -153.6 | -202.3 | -64.87 |
| P/E ratio | -1.65 x | -0.55 x | -0.61 x | -0.64 x | -0.93 x | -1.36 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 145 x | 8.55 x | 5.4 x | 4.32 x | 1.77 x | 0.74 x |
| EV / Revenue | -2.8 x | -17 x | 5.4 x | -15.8 x | -8.55 x | -1.15 x |
| EV / EBITDA | 0.04 x | 1.23 x | -0.65 x | 1.62 x | 1.65 x | 0.48 x |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Price to Book | 0.73 x | 0.29 x | - | 0.57 x | 0.69 x | 1.34 x |
| Nbr of stocks (in thousands) | 37,285 | 37,661 | 37,966 | 38,128 | - | - |
| Reference price 2 | 4.900 | 1.300 | 1.120 | 1.100 | 1.100 | 1.100 |
| Announcement Date | 30/03/22 | 29/03/23 | 21/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.215 | 0.231 | 1.26 | 5.729 | 7.876 | 9.702 | 23.65 | 56.34 |
| EBITDA 1 | - | -47.15 | -83.1 | -79.08 | -65.12 | -94.6 | -122.2 | -136 |
| EBIT 1 | - | -49.18 | -92.79 | -90.32 | -76.2 | -88.44 | -83.82 | -72.51 |
| Operating Margin | - | -21,290.91% | -7,364.13% | -1,576.56% | -967.45% | -911.54% | -354.42% | -128.7% |
| Earnings before Tax (EBT) 1 | - | -60.73 | -98.59 | -88.1 | -69.2 | -80.67 | -67.48 | -36.5 |
| Net income 1 | - | -60.73 | -98.59 | -88.1 | -69.2 | -80.67 | -68.28 | -50.71 |
| Net margin | - | -26,289.18% | -7,824.68% | -1,537.76% | -878.58% | -831.46% | -288.72% | -90.01% |
| EPS 2 | -2.180 | - | -2.970 | -2.360 | -1.830 | -1.728 | -1.182 | -0.8067 |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 10/08/20 | 31/03/21 | 30/03/22 | 29/03/23 | 21/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.752 | 0.508 | 0.813 | 1.393 | 2.112 | 1.411 | 1.826 | 1.433 | 2.528 | 2.089 | 2.251 | 2.158 | 2.724 | 2.569 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -23.53 | -27.08 | -23.88 | -23.06 | -22.35 | -21.04 | -18.42 | -19.83 | -18.18 | -19.77 | -20.41 | -21.4 | -21.55 | -22.68 |
| Operating Margin | -3,128.46% | -5,329.72% | -2,936.78% | -1,655.35% | -1,058.05% | -1,491.14% | -1,008.49% | -1,383.95% | -719.26% | -946.19% | -906.75% | -991.55% | -791.12% | -882.82% |
| Earnings before Tax (EBT) 1 | -23.4 | -27.16 | -23.68 | -22.66 | -21.76 | -20 | -16.98 | -18.06 | -16.26 | -17.9 | -18.7 | -19.94 | -20.4 | -21.62 |
| Net income 1 | -23.4 | -27.16 | -23.68 | -22.66 | -21.76 | -20 | -16.98 | -18.06 | -16.26 | -17.9 | -18.7 | -19.94 | -20.4 | -21.62 |
| Net margin | -3,111.04% | -5,345.87% | -2,912.42% | -1,626.99% | -1,030.26% | -1,417.22% | -929.9% | -1,260.08% | -643.08% | -857.01% | -830.85% | -924.02% | -749.01% | -841.65% |
| EPS 2 | -0.6300 | -0.7300 | -0.6400 | -0.6100 | -0.5800 | -0.5300 | -0.4500 | -0.4800 | -0.4300 | -0.4700 | -0.4933 | -0.4300 | -0.4200 | -0.4000 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 09/11/21 | 30/03/22 | 12/05/22 | 10/08/22 | 10/11/22 | 29/03/23 | 11/05/23 | 07/08/23 | 09/11/23 | 21/03/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 12 | 186 | 146 | - | 196 | 244 | 107 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | -41.8% | - | -55.5% | -48.2% | -64.7% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | - | 6.690 | 4.540 | - | 1.940 | 1.600 | 0.8200 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | - | 3.26 | - | 1.95 | - | 0.39 | 0.41 | 0.43 |
| Capex / Sales | - | 1,412.12% | - | 34.09% | - | 4.02% | 1.73% | 0.76% |
| Announcement Date | 10/08/20 | 31/03/21 | 30/03/22 | 29/03/23 | 21/03/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.1
USD
Average target price
4.45
USD
Spread / Average Target
+304.55%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -1.79% | 41.94M | |
| -1.65% | 103B | |
| +6.75% | 101B | |
| +5.71% | 23.07B | |
| -12.60% | 22.23B | |
| -9.70% | 18.05B | |
| -39.98% | 17.18B | |
| -10.17% | 16.94B | |
| +6.12% | 14.07B | |
| +35.47% | 12.35B |
- Stock Market
- Equities
- BOLT Stock
- Financials Bolt Biotherapeutics, Inc.
